Technical Analysis for ADAP - Adaptimmune Therapeutics plc

Grade Last Price % Change Price Change
grade C 7.86 -0.76% -0.06
ADAP closed down 0.76 percent on Tuesday, December 12, 2017, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Flat Down
See historical ADAP trend table...

Date Alert Name Type % Chg
Dec 12 Fell Below 50 DMA Bearish 0.00%
Dec 12 Bollinger Band Squeeze Range Contraction 0.00%
Dec 12 NR7 Range Contraction 0.00%
Dec 12 Wide Bands Range Expansion 0.00%
Dec 12 Oversold Stochastic Weakness 0.00%
Dec 11 50 DMA Support Bullish -0.76%
Dec 11 Bollinger Band Squeeze Range Contraction -0.76%
Dec 11 BB Squeeze + Upper Band Touch Range Contraction -0.76%
Dec 11 Outside Day Range Expansion -0.76%
Dec 11 Wide Bands Range Expansion -0.76%

Older signals for ADAP ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Is ADAP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.29
52 Week Low 3.76
Average Volume 243,230
200-Day Moving Average 6.1475
50-Day Moving Average 7.8638
20-Day Moving Average 7.9875
10-Day Moving Average 7.9885
Average True Range 0.4536
ADX 11.08
+DI 21.66
-DI 14.6
Chandelier Exit (Long, 3 ATRs ) 7.3492
Chandelier Exit (Short, 3 ATRs ) 8.6608
Upper Bollinger Band 8.3741
Lower Bollinger Band 7.6009
Percent B (%b) 0.34
BandWidth 9.680125
MACD Line 0.0357
MACD Signal Line 0.0585
MACD Histogram -0.0228
Fundamentals Value
Market Cap 735.06 Million
Num Shares 93.5 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -7.94
Price-to-Sales 39.39
Price-to-Book 2.97
PEG Ratio 0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.25
Resistance 3 (R3) 8.26 8.14 8.19
Resistance 2 (R2) 8.14 8.04 8.14 8.16
Resistance 1 (R1) 8.00 7.98 7.94 7.99 8.14
Pivot Point 7.88 7.88 7.85 7.88 7.88
Support 1 (S1) 7.74 7.78 7.68 7.73 7.58
Support 2 (S2) 7.62 7.72 7.62 7.56
Support 3 (S3) 7.48 7.62 7.54
Support 4 (S4) 7.47